Close Menu

gel-drop PCR microarray

The agreement provides Akonni access to nucleic acid sequences, primers, and probes for several important biothreat agents, which it will incorporate into molecular tests on its TruArray and TruSentry platforms.

In addition, Akonni is developing tests based on the biochip technology for a number of other infectious agents, and is designing and testing an integrated instrument platform to perform the tests, with the ultimate goal of seeking US regulatory clearance.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.